GLSI vs. ZVRA, TYRA, TSHA, OPT, BCYC, KURA, SEPN, ABVX, MAZE, and PRME
Should you be buying Greenwich LifeSciences stock or one of its competitors? The main competitors of Greenwich LifeSciences include Zevra Therapeutics (ZVRA), Tyra Biosciences (TYRA), Taysha Gene Therapies (TSHA), Opthea (OPT), Bicycle Therapeutics (BCYC), Kura Oncology (KURA), Septerna (SEPN), Abivax (ABVX), Maze Therapeutics (MAZE), and Prime Medicine (PRME). These companies are all part of the "pharmaceutical products" industry.
Greenwich LifeSciences vs. Its Competitors
Greenwich LifeSciences (NASDAQ:GLSI) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.
In the previous week, Zevra Therapeutics had 10 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 10 mentions for Zevra Therapeutics and 0 mentions for Greenwich LifeSciences. Zevra Therapeutics' average media sentiment score of 0.73 beat Greenwich LifeSciences' score of 0.00 indicating that Zevra Therapeutics is being referred to more favorably in the news media.
Greenwich LifeSciences presently has a consensus target price of $39.00, suggesting a potential upside of 269.67%. Zevra Therapeutics has a consensus target price of $23.14, suggesting a potential upside of 100.20%. Given Greenwich LifeSciences' higher possible upside, equities analysts clearly believe Greenwich LifeSciences is more favorable than Zevra Therapeutics.
Greenwich LifeSciences has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500. Comparatively, Zevra Therapeutics has a beta of 1.97, indicating that its share price is 97% more volatile than the S&P 500.
Greenwich LifeSciences has a net margin of 0.00% compared to Zevra Therapeutics' net margin of -226.78%. Zevra Therapeutics' return on equity of -201.05% beat Greenwich LifeSciences' return on equity.
4.2% of Greenwich LifeSciences shares are owned by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are owned by institutional investors. 51.7% of Greenwich LifeSciences shares are owned by insiders. Comparatively, 2.4% of Zevra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Greenwich LifeSciences has higher earnings, but lower revenue than Zevra Therapeutics. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Zevra Therapeutics beats Greenwich LifeSciences on 11 of the 16 factors compared between the two stocks.
Get Greenwich LifeSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLSI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GLSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Greenwich LifeSciences Competitors List
Related Companies and Tools
This page (NASDAQ:GLSI) was last updated on 7/9/2025 by MarketBeat.com Staff
